Category: Novo Nordisk
-
Novo Nordisk targets Canadian pharma giant Apotex in new oral semaglutide patent infringement suit
Novo Nordisk has sued Canada’s Apotex in the United States District Court for the District of New Jersey over the alleged infringement of six patents related to its oral weightloss drug Rybelsus.
-
Novo Nordisk files fresh semaglutide patent infringement suit in District of Delaware
Novo Nordisk has sued telehealth medication provider Hims & Hers over the infringement of one of its semaglutide patents, as the company faces headwinds over its weightloss drugs for the first time in nearly a decade.
-
“Principles of good litigation are universal”: Novo Nordisk Associate General Counsel Raquel Frisardi
“Whether you are litigating a contract, patent infringement, or a crime – there are certain behaviors as a litigator that get you better results, and I think those are very universal,” Raquel Frisardi told ip fray in an interview during Kisaco’s Patent Litigation Europe Summit.
-
“Limited” UPC impact on global pharma patent strategies, interim licenses debate, “seismic” changes at the PTAB: highlights from Patent Litigation Europe
An overwhelming consensus that life sciences companies prefer to litigate in parallel national courts rather than in the UPC, and an intense debate about the use of interim licenses over arbitration, were among the highlights of the second and third days of Kisaco’s annual Patent Litigation Europe in Amsterdam this week.
-
UPC success rate, EPO convergence debate and changing the “status quo”: day one of Patent Litigation EuropeÂ
ip fray breaks down the highlights from the first day of the fourth annual Patent Litigation Summit Europe, which featured a full day agenda dedicated to Unified Patent Court Litigation discussions.
-
China’s top court grants Novo Nordisk win over key Ozempic patent
China’s Supreme People’s Court has upheld a lower court’s decision recognizing the validity of Novo Nordisk’s compound patent related to semaglutide, which is found in the company’s blockbuster drugs Ozempic, Wegovy, and Rybelsus.
-
Novo Nordisk suffers another loss in efforts to extend key Ozempic patent in Brazil
Brazil’s Superior Tribunal de Justiça has issued its first-ever decision on patent term adjustment, ruling that Novo Nordisk’s request to extend its Ozempic-related patent is unconstitutional because a drugmaker’s rights to a patent term cannot override society’s rights to affordable medicine.
-
10x Genomics, Moderna, Novo Nordisk among newly confirmed speakers for Patent Litigation Europe event (pharma & tech) next month
Eric Whitaker, Chief Legal Officer at 10x Genomics, Karen Guo, Senior Director of Patents & IP at Novo Nordisk, and Katherine Hinterberg, Senior Director of Patent Litigation at Moderna, will speak at Kisaco Research’s annual Pharma and Biotech Patent Litigation Europe in Amsterdam.
-
Delhi High Court allows Dr. Reddy’s to enter Indian semaglutide market in March 2026, dismisses Novo Nordisk appeal
In a landmark judgment, the Delhi High Court has ruled that Novo Nordisk failed to prove why it should be granted an interim injunction against Dr. Reddy’s, but has ordered the latter not to proceed with sales in Indian until the patent-in-suit expires on March 20, 2026.
-
PI spate: Novo Nordisk just obtained 29 injunctions (26 over patent, 3 over UCL) against semaglutide rivals in Germany, served at CPHI fair
Context: What’s new: Novo Nordisk has just obtained, served and enforced a whopping 29 preliminary injunctions (PIs) against (mostly Asian and to a lesser extent European) companies offering the active pharmaceutical ingredient semaglutide and/or pharmaceuticals containing semaglutide at the CPHI fair. The pan-European law firm of Hoyng Rokh Monegier, in collaboration with UK firm Bristows,…